Cancer Immunology and Oncolytic Virology: Technologies and Global Markets - KTEN.com - No One Gets You Closer

Cancer Immunology and Oncolytic Virology: Technologies and Global Markets

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, April 24, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Immunology and Oncolytic Virology: Technologies and Global Markets

http://www.reportlinker.com/p02070062/Cancer-Immunology-and-Oncolytic-Virology-Technologies-and-Global-Markets.html

REPORT HIGHLIGHTS

The global cancer immunotherapies market reached $30.8 billion in 2012. This market is expected to grow to nearly $34.3 billion in 2013 and $67.9 billion in 2018 with a compound annual growth rate (CAGR) of 14.7% over the five-year period, 2013 to 2018.

This report provides:

An overview of the global market for cancer immunotherapies
Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018.
Analyses of factors influencing market demand such as clinical guidelines, demographic changes, and market saturation
Technological discussion including the current state, newly issued patents, and pending applications
Profiles of leading companies in the industry.

STUDY GOALS AND OBJECTIVES

This report, PHM129A Cancer Immunology and Oncolytic Virology: Technologies and Global Markets provides an overview of the current and potential global market for cancer immunotherapy and virology. The report provides comprehensive information on a number of the most common cancers, highlighting global incidence and prevalence. It identifies the need for more effective drugs for treatment of these diseases. The key objective is to present a comprehensive analysis of the current state of cancer immunotherapy and where this field is going. A second objective is to examine the current state of oncolytic virology and where this nascent field appears to be heading. Important trends in each field, clinical trials and results, new developments and sales forecasts for cancer immunotherapy from 2011 through 2018 are provided in this report. In addition, sales forecasts are presented for oncolytic virology covering the years 2011 through 2023. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the cancer market. The report also addresses opportunities for future players.

REASONS FOR DOING THE STUDY

This study was conducted to provide detailed information regarding the new area of immunology-based treatment options for cancer. There is an increasing need for new and innovative drugs. This young industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer, more efficacious treatment strategies. This study looks at the latest types of treatment strategies based on immunology, as well as the new field of oncolytic virotherapy, a field still in its infancy showing immense promise for the clinical management of cancer.This BCC Research market research report will increase the reader's awareness of current and emerging drugs and technologies for many cancers.

SCOPE OF REPORT

The scope of this study entails the current immunology therapeutics markets for several of the most common cancers. The sectors covered are colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines and other cancer treatment immunology products. Vaccines against HPV and hepatitis B are included; while such vaccines act only indirectly against cancer, they do serve to protect against the disease. Also covered is oncolytic virology, so new that its market tables have been presented separately from the immunotherapy tables. The report also includes discussion of the regulatory environment, current and developing technologies, cancer incidence, market projections and market share, along with latest trends and clinical trials.

INTENDED AUDIENCE

This report is an exhaustive study on the global oncolytic immunotherapy and virology market, with important statistics and analysis on existing drugs, drug candidates in clinical testing, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in oncolytic immunotherapy strategies for several of the most common cancers, and does so from the point of view of manufacturers, product suppliers, healthcare providers, and consumers of oncology products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the sector. This report shows current trends in oncolytic immunotherapy and virology, new developments and revenue prospects for these areas. The report provides market data for 2011 to 2018 for oncolytic immunotherapy, and 2011 to 2023 for cancer virology. It also covers commercial prospects and the likely revenues in both oncolytic immunotherapy and virology.

INFORMATION SOURCES

A number of companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC Research spoke with officials within the industry and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

Chapter- 1: INTRODUCTION 3

STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH ONLINE SERVICES
DISCLAIMER

Chapter- 2: SUMMARY 2

CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, THROUGH 2018
Figure Summary : CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, 2011-2018

Chapter- 3: OVERVIEW

HISTORY AND CURRENT STATE OF CANCER IMMUNOLOGY
SUMMARY OF GLOBAL HUMAN CANCER TRENDS THROUGH 2018

Chapter- 4: OVERVIEW OF CANCER IMMUNOTHERAPY

MECHANISMS OF ACTION
BIOLOGICAL RESPONSE MODIFIERS
CANCER VACCINES
OTHER IMMUNOTHERAPY PRODUCTS FOR CANCER TREATMENT
EXPANDED INFORMATION REGARDING SELECTED CLINICAL TRIALS

Chapter- 5: ONCOLYTIC VIROTHERAPY

VIROTHERAPY
ONCOLYTIC VIROLOGY
NEWS AND DEALS IN CANCER IMMUNOTHERAPY AND VIROLOGY
GOVERNMENT REGULATIONS
INDUSTRY STRUCTURE

Chapter- 6: MAJOR MARKETS

MARKET FOR ONCOLYTIC VIROLOGY PRODUCTS
Table 32 : GLOBAL MARKET FOR CANCER IMMUNOLOGY BY SEGMENT, THROUGH 2018
Table 33 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE U.S., THROUGH 2018
Table 34 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN CANADA THROUGH 2018
Table 35 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE EU THROUGH 2018
Table 36 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN JAPAN, THROUGH 2018
Table 37 : VALUE OF CANCER IMMUNOLOGY PRODUCTS FOR REST OF WORLD, (THROUGH 2018)
Table 38 : CANCER IMMUNOLOGY MARKET BY INDICATION, THROUGH 2018
Table 39 : CANCER IMMUNOLOGY SALES BY INDICATION (PROSTATE CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 40 : CANCER IMMUNOLOGY SALES BY INDICATION (BREAST CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 41 : CANCER IMMUNOLOGY SALES BY INDICATION (LUNG CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 42 : CANCER IMMUNOLOGY SALES BY INDICATION (BRAIN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 43 : CANCER IMMUNOLOGY SALES BY INDICATION (HEAD & NECK CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 44 : CANCER IMMUNOLOGY SALES BY INDICATION (OVARIAN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 45 : CANCER IMMUNOLOGY SALES BY INDICATION (CERVICAL CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 46 : CANCER IMMUNOLOGY SALES BY INDICATION (PANCREATIC CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 47 : CANCER IMMUNOLOGY SALES BY INDICATION (MELANOMA CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 48 : CANCER IMMUNOLOGY SALES BY INDICATION (OTHER CANCERS) AND GEOGRAPHIC REGION, THROUGH 2018
Table 49 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: COLONY STIMULATING FACTORS, THROUGH 2018
Table 50 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERFERON ALFA AND GAMMA PRODUCTS, THROUGH 2018
Table 51 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERLEUKIN PRODUCTS, THROUGH 2018
Table 52 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2018
Table 53 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: CANCER VACCINES, THROUGH 2018
Table 54 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2018

Chapter- 7: TECHNOLOGY

PRODUCTION OF MONOCLONAL ANTIBODIES
PATENT EVALUATION

Chapter- 8: COMPANY PROFILES

SELECTED COMPANY PROFILES

List of Tables

CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, THROUGH 2018
Table 1 : GLOBAL PROSTATE CANCER INCIDENCE AND MORTALITY, 2012
Table 2 : GLOBAL LEUKEMIA INCIDENCE AND MORTALITY, 2012
Table 3 : GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2012
Table 4 : BREAST CANCER INCIDENCE, 2012
Table 5 : PROGNOSIS OF BREAST CANCER BASED UPON STAGE
Table 6 : GLOBAL MELANOMA CANCER INCIDENCE AND MORTALITY, 2012
Table 7 : GLOBAL OVARIAN CANCER INCIDENCE AND MORTALITY, 2012
Table 8 : RELATIVE FIVE-YEAR SURVIVAL RATE FOR INVASIVE EPITHELIAL OVARIAN CANCER
Table 9 : GLOBAL CERVICAL CANCER INCIDENCE AND MORTALITY, 2012
Table 10 : AVASTIN SALES AND FORECAST, THROUGH 2018
Table 11 : FIVE-YEAR RELATIVE SURVIVAL OF CERVIX UTERI CANCER PATIENTS, BASED ON STAGE AT DIAGNOSIS
Table 12 : GLOBAL LUNG CANCER INCIDENCE AND MORTALITY, 2012
Table 13 : STAGES OF LUNG CANCER
Table 14 : NON-SMALL CELL LUNG CANCER FIVE-YEAR SURVIVAL RATES BY STAGE
Table 15 : GLOBAL BRAIN CANCER INCIDENCE AND MORTALITY, 2012
Table 16 : GLOBAL MULTIPLE MYELOMA CANCER INCIDENCE AND MORTALITY, 2012
Table 17 : GLOBAL PANCREATIC CANCER INCIDENCE AND MORTALITY, 2012
Table 18 : EXOCRINE PANCREATIC CANCER FIVE-YEAR SURVIVAL RATE
Table 19 : GLOBAL HUMAN CANCER TRENDS, 2011-2018
Table 20 : U.S. HUMAN CANCER TRENDS, 2011-2018
Table 21 : CANADIAN HUMAN CANCER TRENDS, 2011-2018
Table 22 : EUROPEAN HUMAN CANCER TRENDS, 2011-2018
Table 23 : JAPANESE HUMAN CANCER TRENDS, 2011-2018
Table 24 : REST OF WORLD HUMAN CANCER TRENDS, 2011-2018
Table 25 : KNOWN OCCUPATIONAL EXPOSURE RISKS ASSOCIATED WITH CANCER
Table 26 : COLONY-STIMULATING FACTORS ON THE MARKET
Table 27 : SELECTED INTERFERON PRODUCTS ON THE MARKET
Table 28 : SELECTED DEVELOPMENTS IN INTERLEUKINS FOR CANCER THERAPY
Table 29 : SELECTED APPROVED MONOCLONAL ANTIBODIES
Table 30 : ELECTED MABS IN CLINICAL TESTING FOR INITIAL APPROVAL OR FOR ADDITIONAL INDICATIONS
Table 31 : SELECTED CLINICAL TRIALS OF IMMUNOTHERAPY PRODUCTS
Table 32 : GLOBAL MARKET FOR CANCER IMMUNOLOGY BY SEGMENT, THROUGH 2018
Table 33 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE U.S., THROUGH 2018
Table 34 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN CANADA THROUGH 2018
Table 35 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN THE EU THROUGH 2018
Table 36 : VALUE OF CANCER IMMUNOLOGY PRODUCTS IN JAPAN, THROUGH 2018
Table 37 : VALUE OF CANCER IMMUNOLOGY PRODUCTS FOR REST OF WORLD, (THROUGH 2018)
Table 38 : CANCER IMMUNOLOGY MARKET BY INDICATION, THROUGH 2018
Table 39 : CANCER IMMUNOLOGY SALES BY INDICATION (PROSTATE CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 40 : CANCER IMMUNOLOGY SALES BY INDICATION (BREAST CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 41 : CANCER IMMUNOLOGY SALES BY INDICATION (LUNG CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 42 : CANCER IMMUNOLOGY SALES BY INDICATION (BRAIN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 43 : CANCER IMMUNOLOGY SALES BY INDICATION (HEAD & NECK CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 44 : CANCER IMMUNOLOGY SALES BY INDICATION (OVARIAN CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 45 : CANCER IMMUNOLOGY SALES BY INDICATION (CERVICAL CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 46 : CANCER IMMUNOLOGY SALES BY INDICATION (PANCREATIC CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 47 : CANCER IMMUNOLOGY SALES BY INDICATION (MELANOMA CANCER) AND GEOGRAPHIC REGION, THROUGH 2018
Table 48 : CANCER IMMUNOLOGY SALES BY INDICATION (OTHER CANCERS) AND GEOGRAPHIC REGION, THROUGH 2018
Table 49 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: COLONY STIMULATING FACTORS, THROUGH 2018
Table 50 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERFERON ALFA AND GAMMA PRODUCTS, THROUGH 2018
Table 51 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: INTERLEUKIN PRODUCTS, THROUGH 2018
Table 52 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: THERAPEUTIC MONOCLONAL ANTIBODIES, THROUGH 2018
Table 53 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: CANCER VACCINES, THROUGH 2018
Table 54 : CANCER IMMUNOLOGY PRODUCT SALES BY CATEGORY AND REGION: OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2018
Table 55 : GLOBAL ONCOLYTIC VIROTHERAPY MARKET, THROUGH 2023
Table 56 : ONCOLYTIC VIROTHERAPY MARKET BY REGION, THROUGH 2023
Table 57 : ONCOLYTIC VIROLOGY OUTLOOK BY CANCER TYPE, THROUGH 2023
Table 58 : SELECTED PATENTS IN CANCER IMMUNOLOGY AND VIROLOGY, 2005 TO 2013

List of Figures

CANCER IMMUNOTHERAPIES MARKET BY GEOGRAPHICAL REGION, 2011-2018
Figure 1 : GLOBAL HUMAN CANCER TRENDS, 2011-2018
Figure 2 : MARKET SHARES OF LEADERS IN CANCER IMMUNOLOGY, 2013

To order this report: Cancer Immunology and Oncolytic Virology: Technologies and Global Markets
http://www.reportlinker.com/p02070062/Cancer-Immunology-and-Oncolytic-Virology-Technologies-and-Global-Markets.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

©2012 PR Newswire. All Rights Reserved.